Skip to main content

Table 2 Clinical characteristics and pathologic data of 20 patients enrolled in the study

From: EZH2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitable molecular target in combination treatment approaches

Clinical characteristics

Number of patients (%)

Gender

 

 Male

15 (75)

 Female

5 (25)

WBC

 

 ≤20.000/mm3

6 (30)

 >20.000/mm3

14 (70)

FAB phenotype

 

 L1

4 (20)

 L2

16 (80)

Disease Status

 

 Relapsed

9 (45)

 No relapsed

11 (55)

Risk

 

 Standard

3 (15)

 High

17 (85)

PDN

 

 GR

7 (35)

 PR

13 (65)

  1. WBC White Blood Cell, PDN Prednisone, GR Good Responders, PR Poor Responders